       Document 0460
 DOCN  M9550460
 TI    HIV therapy advances. Early antiretroviral therapy.
 DT    9505
 AU    Cooper DA; National Centre in HIV Epidemiology and Clinical Research,;
       Faculty of Medicine, University of New South Wales, St Vincent's;
       Hospital Medical Centre, Sydney, Australia.
 SO    AIDS. 1994 Sep;8 Suppl 3:S9-14. Unique Identifier : AIDSLINE
       MED/95142953
 AB    AIM: To review evidence suggesting that antiretroviral therapy should be
       initiated at an early stage in HIV infection. METHOD: Review of
       published data. CONCLUSIONS: There are arguments both for and against
       early antiretroviral therapy. Although the reasons against are
       undoubtedly valid, evidence of greater efficacy, less toxicity and a
       delay in the development of resistance outweigh the possible
       disadvantages. Moreover, for some patients, early therapy may provide a
       chance of future benefits from more useful but currently untried
       treatments.
 DE    Antiviral Agents/*THERAPEUTIC USE  Clinical Trials  CD4 Lymphocyte Count
       Drug Therapy, Combination  Human  HIV Infections/*DRUG
       THERAPY/IMMUNOLOGY/*PHYSIOPATHOLOGY  Multicenter Studies  Retroviridae
       Time Factors  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

